Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT06466850, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Isfahan University of Medical Sciences
- Trial code
- NCT06466850
- Record updated
- 15 September 2025
- Original description
Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).Read full original descriptionShow less
The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).
OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS).
MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.
Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.
This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.
Inclusion: Chronic history (for at least 3 months) of knee joint pain; Body mass index (BMI) between 21.5 and 29.5; Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale).
Exclusion: Hyaluronic acid infiltration within the previous six months; Rheumatoid arthritis and other rheumatic diseases; Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk; Hemoglobin levels <10 g/dL; Varus or valgus more than 10 degrees; lateral subluxation of the patella; Deformity at the joint levels or adjacent to the knee due to fracture or any other injury; Complete rupture of the ligament and meniscus leading to laxity or locking.